The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10520 malaria professionals are enjoying the free benefits of MalariaWorld today

atorvastatin

Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene

June 10, 2010 - 12:48 -- Patrick Sampao
Author(s): 
Nathalie W., Sébastien B., et al.
Reference: 
J. Antimicrob. Chemother., July 2010; 65: 1387 - 1394.

The aim of the study was to assess the in vitro potentiating effects of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, in combination with mefloquine, chloroquine or monodesethylamodiaquine against Plasmodium falciparum and to evaluate whether the effects of atorvastatin could be associated with mutations or gene copy number in multidrug resistance (MDR)-like protein genes.

Medical Condition: 

Open Access | Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum

May 27, 2010 - 11:29 -- Patrick Sampao
Author(s): 
Parquet V, Henry M, Wurtz N, Dormoi J, Briolant S, Gil M, Baret E, Amalvict R, Rogier C, Pradines B
Reference: 
Malaria Journal 2010, 9:139 (25 May 2010)

Genotypes and gene copy number were assessed for pfcrt, pfmdr1, pfmdr2, pfmrp genes. In addition, the number of DNNND, DDNHNDNHNN repeats in pfnhe-1 ms4760 and the ms4760 profile were determined for each strains of P. falciparum.

Medical Condition: 

Letter: Atorvastatin as a Potential Antimalarial Drug: In Vitro Synergy in Combinational Therapy with Dihydroartemisinin

January 28, 2010 - 12:17 -- Kabogo Ndegwa
Author(s): 
Hélène Savini, Jean Baptiste Souraud, Sébastien Briolant, Eric Baret, Rémy Amalvict, Christophe Rogier, and Bruno Pradines
Reference: 
Antimicrobial Agents and Chemotherapy, February 2010, p. 966-967, Vol. 54, No. 2

No abstract available

Medical Condition: 
Subscribe to RSS - atorvastatin